![Daniel Rankin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 714 855 $ al 31/10/2026
Daniel Rankin currently works at Swedish Orphan Biovitrum AB, as Head-Strategy & Corporate Development.
Dr. Rankin received his graduate degree from the University of Leiden, doctorate degree from the University of Helsinki, and undergraduate degree from the University of York.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 12/06/2026 | 14.338 ( 0 % ) | 714 855 $ | 31/10/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Corporate Officer/Principal | 01/01/2017 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
University of Leiden
 University of Leiden Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Helsinki
 University of Helsinki Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Swedish Orphan Biovitrum AB
 Swedish Orphan Biovitrum AB Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceuticals and orphan drugs in the areas of hematology, immunology and specialty care | Health Technology |
University of York
 University of York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
